On Thursday's edition of Market Checkup, The Motley Fool's health-care focused show for investors, Fool health-care analyst David Williamson sheds some light on what's driving the biggest movers in the health-care space today.
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) popped 8% today on word from British newspapers that Eli Lilly (NYSE:LLY), and possibly GlaxoSmithKline (NYSE:GSK), were interested in buying the biotech. To David however, the story just doesn't add up. In this segment, he looks at why the deal wouldn't make sense for Eli Lilly or Glaxo, and why he isn't putting a lot of credence behind these reports.
David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Ariad Pharmaceuticals Stock Nearly Doubled in January
The drugmaker's stock soared last month on a rich buyout offer from Japan's Takeda Pharmaceutical.
These 3 Stocks Have Doubled Since Election Day
Find out why these stocks have soared during the post-election rally.
Why Ariad Pharmaceuticals, VCA, and Exact Sciences Jumped Today
Despite market losses, these stocks gained ground. Find out why.